235 related articles for article (PubMed ID: 10446299)
1. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
Koning GA; Morselt HW; Velinova MJ; Donga J; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
Biochim Biophys Acta; 1999 Aug; 1420(1-2):153-67. PubMed ID: 10446299
[TBL] [Abstract][Full Text] [Related]
2. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.
Koning GA; Kamps JA; Scherphof GL
Cancer Detect Prev; 2002; 26(4):299-307. PubMed ID: 12430634
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells.
Koning GA; Gorter A; Scherphof GL; Kamps JA
Br J Cancer; 1999 Aug; 80(11):1718-25. PubMed ID: 10468287
[TBL] [Abstract][Full Text] [Related]
4. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
[TBL] [Abstract][Full Text] [Related]
5. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
[TBL] [Abstract][Full Text] [Related]
6. Immunotargeting of liposomes containing lipophilic antitumor prodrugs.
Mori A; Kennel SJ; Huang L
Pharm Res; 1993 Apr; 10(4):507-14. PubMed ID: 8483832
[TBL] [Abstract][Full Text] [Related]
7. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases.
Koning GA; Morselt HW; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
Pharm Res; 2001 Sep; 18(9):1291-8. PubMed ID: 11683242
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies of the preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome-target cell binding by cytofluorometry and electron microscopy.
Schwendener RA; Trüb T; Schott H; Langhals H; Barth RF; Groscurth P; Hengartner H
Biochim Biophys Acta; 1990 Jul; 1026(1):69-79. PubMed ID: 2378882
[TBL] [Abstract][Full Text] [Related]
11. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
12. Integrinβ6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma.
Liang B; Shahbaz M; Wang Y; Gao H; Fang R; Niu Z; Liu S; Wang B; Sun Q; Niu W; Liu E; Wang J; Niu J
Clin Cancer Res; 2015 Mar; 21(5):1183-95. PubMed ID: 25549721
[TBL] [Abstract][Full Text] [Related]
13. In vivo distribution and antitumour activity of liposomal 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine.
Van Borssum Waalkes M; Fichtner I; Dontje B; Lemm M; Becker M; Arndt D; Scherphof GL
J Microencapsul; 1992; 9(3):335-46. PubMed ID: 1403484
[TBL] [Abstract][Full Text] [Related]
14. Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison.
Koning GA; Morselt HW; Gorter A; Allen TM; Zalipsky S; Scherphof GL; Kamps JA
Pharm Res; 2003 Aug; 20(8):1249-57. PubMed ID: 12948023
[TBL] [Abstract][Full Text] [Related]
15. Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer.
Kamps JA; Koning GA; Velinova MJ; Morselt HW; Wilkens M; Gorter A; Donga J; Scherphof GL
J Drug Target; 2000; 8(4):235-45. PubMed ID: 11144234
[TBL] [Abstract][Full Text] [Related]
16. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs.
Crosasso P; Brusa P; Dosio F; Arpicco S; Pacchioni D; Schuber F; Cattel L
J Pharm Sci; 1997 Jul; 86(7):832-9. PubMed ID: 9232525
[TBL] [Abstract][Full Text] [Related]
17. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies.
Maruyama K; Takizawa T; Yuda T; Kennel SJ; Huang L; Iwatsuru M
Biochim Biophys Acta; 1995 Mar; 1234(1):74-80. PubMed ID: 7880861
[TBL] [Abstract][Full Text] [Related]
18. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
19. [Study on preparation and biodistribution of PEG-immunoliposomes with active carboxylic terminals].
Zhang YF; Xie SS; Hou XP; Gao X; Zhang S; Chen ZS
Yao Xue Xue Bao; 2000 Nov; 35(11):854-9. PubMed ID: 11218866
[TBL] [Abstract][Full Text] [Related]
20. Interference of macrophages with immunotargeting of liposomes.
Koning GA; Kamps JA; Scherphof GL
J Liposome Res; 2002; 12(1-2):107-19. PubMed ID: 12604044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
